Collateral chemoresistance to anti- microtubule agents in a lung cancer cell line with acquired resistance to erlotinib

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Mizuuchi, Hiroshi ^a,b   Suda, Kenichi ^a,b   Sato, Katsuaki ^a   Tomida, Shuta ^a   Fujita, Yoshihiko ^a   Kobayashi, Yoshihisa ^a   Maehara, Yoshihiko ^b   Sekido, Yoshitaka ^c   Nishio, Kazuto ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; CISPLATIN; DOCETAXEL; ENTINOSTAT; ERLOTINIB; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE INHIBITOR; TUBULIN MODULATOR;

ABCB1 GENE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; H358 CELL LINE; HCC4006 CELL LINE; HCC4006EPR CELL LINE; HCC4006ER CELL LINE; HCC827 CELL LINE; HCC827TRB10 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; PC9 CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ERLOTINIB HYDROCHLORIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; P-GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUBULIN MODULATORS;

EID: 84929486151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123901     Document Type: Article

References (33)

1. Suda K, Tomizawa K, Mitsudomi T (2010) Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29: 49- 60. doi:10.1007/s10555-010-9209-4 PMID: 20108024.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388. doi:10.1056/NEJMoa0909530 PMID: 20573926.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121-128. doi:10.1016/S1470-2045(09)70364-X PMID: 20022809.
4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. (2011) Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742. doi:10.1016/S1470-2045(11)70184-X PMID: 21783417.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246. doi:10.1016/S1470-2045(11)70393-X PMID: 22285168.
6. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T (2012) Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31: 807-814. doi:10.1007/s10555-012-9391-7 PMID: 22736441.
7. Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11: 473-481. doi:10.1038/nrclinonc.2014.104 PMID: 24981256.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. PMID: 17463250.
9. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16: 5489-5498. doi:10.1158/1078-0432.CCR-10-1371 PMID: 21062933.
10. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161. doi:10.1097/JTO.0b013e318216ee52 PMID: 21597390.
11. Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2: e39. doi:10.1038/oncsis.2013.4 PMID: 23552882.
12. Puri N, Salgia R (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7: 9. PMID: 19240370.
13. Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, et al. (2011) Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol 225: 83-95. doi:10.1002/path.2897 PMID: 21598249.
14. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K (2005) Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116: 36-44. PMID: 15761868.
15. Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, et al. (2010) Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 101: 167-172. doi:10.1111/j.1349-7006.2009.01368.x PMID: 19804422.
16. Furugaki K, Iwai T, Moriya Y, Harada N, Fujimoto-Ouchi K (2014) Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer 83: 44-50. doi:10.1016/j.lungcan.2013.10.003 PMID: 24192512.
17. Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T (2014) The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer 135: 1002-1006. doi:10.1002/ijc.28737 PMID: 24458568.
18. Kurahashi I, Fujita Y, Arao T, Kurata T, Koh Y, Sakai K, et al. (2013) A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS One 8: e63249. doi:10.1371/journal.pone.0063249 PMID: 23671674.
19. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, et al. (2007) Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173: 1-9. PMID: 17284363.
20. Breen L, Murphy L, Keenan J, Clynes M (2008) Development of taxane resistance in a panel of human lung cancer cell lines. Toxicol In Vitro 22: 1234-1241. doi:10.1016/j.tiv.2008.04.005 PMID: 18514476.
21. Adams DJ, Knick VC (1995) P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 13: 13-21. PMID: 7499103.
22. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD, et al. (2005) Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 41: 1086-1094. PMID: 15862759.
23. Chen LM, Liang YJ, Zhang X, Su XD, Dai CL, Wang FP, et al. (2009) Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 29: 4597-4604. PMID: 20032409.
24. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, et al. (2013) Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 12: 1829-1836. doi:10.1158/1535-7163.MCT-13-0208 PMID: 23861346.
25. Yang YL, Luo XP, Xian L (2014) The prognostic role of the class III beta-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: A meta-analysis. PLoS One 9: e93997. doi:10.1371/journal.pone.0093997 PMID: 24705847.
26. Li WJ, Zhong SL, Wu YJ, Xu WD, Xu JJ, Tang JH, et al. (2013) Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines. Mol Biol Rep 40: 6143-6150. PMID: 24078162.
27. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y (2009) Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 100: 1701-1707. doi:10.1111/j.1349-7006.2009.01213.x PMID: 19493273.
28. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-726. doi:10.1038/nrc3599 PMID: 24060863.
29. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, et al. (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73: 3051-3061. doi:10.1158/0008-5472.CAN-12-4136 PMID: 23542356.
30. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, et al. (2008) Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment. Clin Cancer Res 14: 6867-6876. doi:10.1158/1078-0432.CCR-08-0093 PMID: 18980981.
31. Kurokawa M, Ise N, Omi K, Goishi K, Higashiyama S (2013) Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes. Cancer Sci 104: 904-911. doi:10.1111/cas.12171 PMID: 23566288.
32. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, et al. (2010) Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 70: 8715-8725. doi:10.1158/0008-5472.CAN-10-0043 PMID: 20959484.
33. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860. doi:10.1038/ng.2330 PMID: 22751098.